Mimic vs Delinea
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mimic is a Palo Alto ransomware defense startup that raised $77M (including a $50M Series A led by GV and Menlo Ventures); detects and blocks ransomware in fractions of a second and achieved FedRAMP Ready status in 2025.
About
Mimic is a cybersecurity company founded in 2023 and headquartered in Palo Alto, California, that specializes in enterprise ransomware defense. Its SaaS platform combines real-time detection, deflection, and rapid recovery to stop ransomware attacks before data is encrypted or exfiltrated. The platform enforces a trusted known-good state on protected systems and blocks unauthorized changes at the exact moment they occur, detecting threats within fractions of a second. Mandiant founder and former CEO Kevin Mandia joined Mimic''s board of directors following its Series A.
Delinea is a privileged access management platform delivering secrets management, privilege elevation, and session controls across cloud, on-premise, and hybrid environments.
About
Delinea is a privileged access management (PAM) company headquartered in Redwood City, California, formed in 2021 through the merger of Thycotic and Centrify — two established PAM vendors whose combination created one of the largest independent players in the privileged access security market. The merger was backed by TPG Capital and brought together Thycotic's Secret Server vault and cloud PAM capabilities with Centrify's identity-centric privileged access controls and zero trust architecture, creating a unified platform that addresses the full spectrum of PAM use cases: vaulting and rotating privileged credentials, enforcing just-in-time privilege elevation, recording and auditing privileged sessions, and managing machine and application secrets at scale.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.